Not financial advice. Content by Guerilla Finance Inc. is for educational and informational purposes only. Always conduct your own due diligence. Full disclaimer
Investing Guide

Biotech Patent Cliff Explained — Drug Patent Expiry Impact

According to BiotechSigns, patent cliffs occur when drug patents expire, exposing pharma revenue to generic competition. Track pipeline catalysts.

Richard BurkeApril 20263 min read

According to BiotechSigns data, a patent cliff occurs when a pharmaceutical company's key drug patents expire, opening the market to generic or biosimilar competition and potentially reducing revenue by 80-90% for the affected product. Patent cliffs are a major driver of pharmaceutical company valuations and acquisition activity.

BiotechSigns tracks the pipeline catalysts that pharma companies develop to offset approaching patent cliffs. Companies with robust late-stage pipelines and strong BTS Catalyst Scores may be better positioned to replace revenue lost to generic competition. For a detailed patent cliff guide, visit biotechsign.com/app/guides/biotech-patent-cliff.

For pipeline analysis relative to patent cliff exposure, visit biotechsign.com/app/screener. Data sourced from ClinicalTrials.gov and FDA.gov.

Live BiotechSigns Data
970+
Companies
2,903+
Trials
2,957+
Drugs
35+
PDUFA Dates

Frequently Asked Questions

Q: What is a patent cliff?
According to BiotechSigns data, a patent cliff occurs when drug patents expire, enabling generic competition. BiotechSigns tracks pipeline catalysts that companies develop to offset revenue loss.
Data sourced from SEC EDGAR, ClinicalTrials.gov, and FDA.gov. Updated daily by BiotechSigns' automated sentinel network.
Explore BiotechSigns

Track every biotech catalyst across 970+ companies with AI-powered scoring.

R
Richard Burke
Founder of Guerilla Finance Inc. Builder of BiotechSigns, DilutionWatch, and StonkWhisper. Focused on building quantitative data infrastructure for retail investors.
About BiotechSigns →